Sirius Collaborates with Vanderbilt on PGx Test | GenomeWeb

NEW YORK (GenomeWeb News) – Diagnostics developer Sirius Genomics will collaborate with Vanderbilt University to study patients in a biomarker study for a drug aimed at treating severe sepsis, the company said today.

The pharmacogenomics company will work with Vanderbilt's Validating Acute Lung Injury biomarkers for Diagnosis (VALID) study to continue development of a diagnostic to assess responsiveness to recombinant human activated Protein C. The drug is sold by Eli Lilly under the trade name Xigris.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.